ArticleDiscover oncology2025
Construction of an eight-basement membrane related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe basement membrane plays a very vital role in impeding cancer progression and metastatic colonization. However, the relationship between basement membrane-related genes (BMRGs) and hepatocellular carcinoma (HCC) remains poorly understood.
methodsThe transcriptome and clinical data of HCC patients were gathered from the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) database, and segmented into training and testing sets, respectively. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses enrichment subsequently analyzed the differentially expressed BMRGs. A novel prognostic BMRGs signature model was constructed by LASSO (least absolute shrinkage and selection operator) in training set and stratified patients into high-risk and low-risk groups, and which was verified in the testing set. Moreover, the accuracy of the new BMRGs signature was detected by receiver operating characteristic curve (ROC) analysis, followed by clinical correlation analysis, immune function analysis and multi-drug resistance analysis to verify the accuracy and clinical practical application value of the new signature.
resultsWe created and verified a novel prognostic BMRGs signature for the prognosis of patients with HCC. The ROC analysis demonstrated that the 1-, 3-, and 5-year survival rates of HCC patients predicted by the prognostic BMRGs signature model based on the BMRGs signature were consistent with those of real patients. In clinical correlation analysis, univariate and multivariate Cox regression analyses validated that the model supports that the prognostic BMRGs signature can be independent risk factors for overall survival (OS) of HCC patients. In addition, the new signature can indeed differentiate the immunological analysis of HCC patients at different risk groups. In the drug sensitivity analysis, the expression levels of the BMRGs in the signatures were found to be related to the sensitivity of common chemotherapy drugs in HCC patients.
conclusionThe newly prognostic BMRGs signature can be used as a prognostic indicator to predict the potential progression trajectory and therapeutic response in HCC, which may also provide sensible recommendations for immunotherapy and the selection of chemotherapeutic agents. Our findings provided a promising insight into BMRGs in HCC and a personalized prediction tool for prognosis and immune responses in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.